Navigating the Future: Breakthrough Strategies for Pancreatic Cancer Treatment
Diagnosed with pancreatic cancer after a routine procedure, Ed O’Connor’s journey began in September 2016. At 75, what started as a standard colonoscopy led to a series of tests revealing a 2 cm tumor on his pancreas, ultimately finding that cancer had spread to nearby lymph nodes. His treatment journey has been both challenging and illuminating, filled with innovative therapies and critical decisions.
The Start of a Treatment Journey
Ed’s encounter with his oncologist, Dr. Muhammad Abbasi, marked a significant turning point. In December 2016, he was introduced to the FOLFIRINOX chemotherapy regimen. Seeking a second opinion, Ed consulted with Dr. John Chabot from Columbia-Presbyterian in New York City, who confirmed a diagnosis of stage IV adenocarcinoma. Unfortunately, surgery was not an option due to the tumor’s location.
- Initial Treatment: Chemotherapy began on December 30, 2016.
- Change of Regimen: After six cycles, Ed switched to the GAX treatment in May 2017.
Innovative Therapies
Incorporating vitamin D and an antimalarial drug into his treatment plan, Ed explored various options to maximize his chances of recovery.
- Zemplar: This synthetic vitamin D was found to enhance the effectiveness of chemotherapy by making pancreatic tumors more susceptible to treatment.
- Hydroxychloroquine (HCQ): Originally developed for malaria, HCQ was believed to disrupt the internal processes of cancer cells.
By the end of 2018, Ed’s tumor became undetectable on scans, prompting his oncologist to suggest a maintenance dose of chemotherapy. This adjustment allowed him to continue receiving treatment while reducing its frequency.
Facing Decisions at a Crossroads
As Ed approached January 2020, he had undergone 87 infusions over three years. Despite the success of his treatment, side effects like anemia and neuropathy weighed heavily on him. The decision to continue or adjust his chemotherapy was critical.
- Consultation with Dr. Abbasi: Together, they decided to reduce his chemotherapy regimen, specifically halting Abraxane, which was likely contributing to his neuropathy, while maintaining Gemzar.
Throughout this battle, Ed faced numerous health challenges unrelated to his cancer, including Lyme disease and infections. Despite these setbacks, Ed credited his medical team and the unwavering support of family and friends for helping him manage his condition effectively.
A Legacy of Hope
Ed’s experience serves as a beacon of hope for those facing similar diagnoses. He embraced the latest treatments while navigating the complexities of cancer care. His story not only highlights the importance of innovative therapies and support but also emphasizes the resilience and courage required in the face of such adversity.
In Loving Memory: Ed O’Connor’s journey with pancreatic cancer lasted nearly four years, during which he shared invaluable insights. Though he is no longer with us, his legacy continues to inspire those fighting this formidable disease.
